Cost-Minimization Analysis of Bevacizumab Compared to Cetuximab and Panitumumab in First-Line Treatment of Kras Wild-Type Metastatic Colorectal Cancer in France
Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.2238
https://www.valueinhealthjournal.com/article/S1098-3015(16)33604-X/fulltext
Section Title :
Disease-Specific Studies
Section Order :
2127
First Page :
A738
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33604-X&doi=10.1016/j.jval.2016.09.2238